General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 271: What percentage of a drug remains in the body after 3 half-lives?

A. 12.50% (Correct Answer)
B. 75%
C. 87.50%
D. 94%

Explanation: ### Explanation **Concept: First-Order Kinetics and Half-Life ($t_{1/2}$)** Most drugs follow first-order kinetics, where a constant **fraction** of the drug is eliminated per unit of time. The half-life is the time required for the plasma concentration of a drug to reduce by 50%. To calculate the percentage of drug remaining after $n$ half-lives, use the formula: **Remaining % = $(1/2)^n \times 100$** * **After 1 half-life:** $100\% \div 2 = 50\%$ remains. * **After 2 half-lives:** $50\% \div 2 = 25\%$ remains. * **After 3 half-lives:** $25\% \div 2 = \mathbf{12.5\%}$ **remains.** (Correct Answer) --- ### Analysis of Options * **Option A (12.50%):** Correct. As calculated above, after three cycles of 50% reduction, 12.5% of the original dose is still present in the systemic circulation. * **Option B (75%):** Incorrect. This represents the amount of drug **eliminated** after 2 half-lives ($100\% - 25\%$). * **Option C (87.50%):** Incorrect. This is the amount of drug **eliminated** after 3 half-lives ($100\% - 12.5\%$). * **Option D (94%):** Incorrect. This is approximately the amount of drug **eliminated** after 4 half-lives (93.75%). --- ### High-Yield NEET-PG Pearls 1. **Steady State:** It takes **4 to 5 half-lives** for a drug to reach steady-state concentration ($C_{ss}$) during constant infusion, and similarly, 4 to 5 half-lives for a drug to be considered "completely" eliminated from the body. 2. **Fixed Fraction vs. Fixed Amount:** In first-order kinetics, a **constant fraction** is eliminated. In zero-order kinetics (e.g., high-dose Aspirin, Alcohol, Phenytoin), a **constant amount** is eliminated regardless of plasma concentration. 3. **Rule of 7:** After 7 half-lives, more than 99% of the drug is eliminated.

Question 272: Alpha-2 adrenergic agonists cause all of the following effects except:

A. Analgesia
B. Hyperalgesia (Correct Answer)
C. Sedation
D. Anxiolysis

Explanation: **Explanation:** Alpha-2 ($\alpha_2$) adrenergic agonists (such as **Clonidine** and **Dexmedetomidine**) act primarily by inhibiting the release of norepinephrine through a negative feedback mechanism at presynaptic nerve terminals. **Why Hyperalgesia is the Correct Answer:** Hyperalgesia refers to an increased sensitivity to pain. $\alpha_2$ agonists are known for their **antinociceptive** properties, meaning they decrease pain perception rather than increasing it. They achieve this by stimulating $\alpha_2$ receptors in the dorsal horn of the spinal cord, which inhibits the release of substance P and other pro-nociceptive neurotransmitters [3]. Therefore, they cause analgesia, not hyperalgesia. **Analysis of Incorrect Options:** * **Analgesia:** As mentioned, $\alpha_2$ agonists provide potent adjunctive pain relief by modulating pain pathways in the spinal cord and brainstem [3]. * **Sedation:** These drugs act on the **locus coeruleus** (the primary noradrenergic nucleus in the brainstem) to decrease sympathetic outflow, leading to a "natural-like" sleep state from which patients can be easily aroused [1], [3]. * **Anxiolysis:** By reducing central sympathetic activity and norepinephrine levels, $\alpha_2$ agonists effectively reduce anxiety and are often used as pre-anesthetic medications. **NEET-PG High-Yield Pearls:** * **Dexmedetomidine:** A highly selective $\alpha_2$ agonist used for ICU sedation; it causes minimal respiratory depression compared to opioids or benzodiazepines [3]. * **Clonidine:** Used in hypertension, opioid withdrawal, and ADHD [4]. * **Side Effects:** The most common side effects are **bradycardia** and **hypotension** due to decreased central sympathetic tone [1], [2]. * **Mechanism:** They are G-protein coupled receptors ($G_i$) that inhibit adenylyl cyclase, leading to decreased cAMP.

Question 273: Which of the following statements best describes long-acting nitrate preparations?

A. Tolerance often develops (Correct Answer)
B. Their effect can be blocked by high doses of beta selective inhibitors
C. Transdermal patches are more likely to be associated with headaches than are sublingual nitrates
D. Oral preparations are more effective than sublingual ones

Explanation: **Explanation:** **1. Why Option A is Correct:** Nitrate tolerance (tachyphylaxis) is a well-documented phenomenon where the therapeutic effect diminishes with continuous exposure. The underlying mechanism involves **oxidative stress**, leading to the depletion of **sulfhydryl (-SH) groups** required for the conversion of nitrates to Nitric Oxide (NO) and the inactivation of mitochondrial aldehyde dehydrogenase. To prevent this, a **"nitrate-free interval"** of 8–12 hours (usually at night) is clinically mandated to restore tissue sensitivity. **2. Why the Other Options are Incorrect:** * **Option B:** The mechanism of action of nitrates (cGMP-mediated vasodilation) is independent of beta-receptors. In fact, beta-blockers are often combined with nitrates to prevent reflex tachycardia. * **Option C:** Sublingual nitrates cause a rapid, high-peak plasma concentration leading to immediate meningeal vasodilation and "throbbing" headaches. Transdermal patches provide a slow, sustained release, making them *less* likely to cause acute, severe headaches compared to the sublingual route. * **Option D:** Oral nitrates undergo extensive **first-pass metabolism** in the liver (especially Nitroglycerin), making them significantly *less* potent and slower-acting than sublingual preparations, which bypass the liver and enter systemic circulation directly. **Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Sublingual Nitroglycerin (GTN) is the DOC for acute anginal attacks; Isosorbide mononitrate is preferred for prophylaxis due to 100% bioavailability. * **Contraindication:** Never co-administer nitrates with **Sildenafil (PDE-5 inhibitors)** as it can lead to catastrophic hypotension. * **Storage:** GTN is volatile and light-sensitive; it should be stored in dark glass containers.

Question 274: Cyclosporin-A acts on which of the following?

A. CD4 cells and T-lymphocytes (Correct Answer)
B. CD8 cells and T-lymphocytes
C. CD16 cells and T-lymphocytes
D. B-lymphocytes

Explanation: **Cyclosporine-A** is a potent immunosuppressant belonging to the **Calcineurin Inhibitor** class. Its primary mechanism of action involves the inhibition of T-cell mediated immunity [1].**Why Option A is Correct:**Cyclosporine binds to an intracellular protein called **Cyclophilin**. This complex inhibits **Calcineurin**, a phosphatase required for the dephosphorylation and activation of the **Nuclear Factor of Activated T-cells (NFAT)**. Without active NFAT, the transcription of **Interleukin-2 (IL-2)** is blocked. Since IL-2 is the primary driver for the proliferation of **CD4+ T-helper cells**, Cyclosporine specifically targets these cells, leading to a suppression of the cell-mediated immune response [1].**Why Other Options are Incorrect:*** **Option B & C:** While Cyclosporine has some effect on CD8+ (Cytotoxic) T-cells, its primary and most potent inhibitory effect is on the IL-2 production from **CD4+ cells**. CD16 is a marker for Natural Killer (NK) cells, which are not the primary target of this drug.* **Option D:** Cyclosporine does not directly inhibit B-lymphocytes. Any reduction in humoral immunity is secondary to the lack of T-cell help (CD4+ cells) required for B-cell activation.**High-Yield Clinical Pearls for NEET-PG:*** **Therapeutic Uses:** Prevention of graft-versus-host disease in organ transplants, Rheumatoid Arthritis, and Psoriasis [2].* **Side Effects (High Yield):** Nephrotoxicity (most common), Gingival Hyperplasia, Hirsutism, Hypertension, and Neurotoxicity (tremors) [2].* **Monitoring:** It has a narrow therapeutic index; hence, Therapeutic Drug Monitoring (TDM) is essential.* **Metabolism:** Metabolized by **CYP3A4**; avoid grapefruit juice as it increases drug levels.

Question 275: All of the following muscle relaxants are metabolized in the liver except:

A. Pancuronium
B. Vecuronium
C. Rocuronium
D. Mivacurium (Correct Answer)

Explanation: **Explanation:** The metabolism of neuromuscular blocking agents (NMBAs) is a high-yield topic for NEET-PG, as it determines the drug's duration of action and safety profile in organ failure. **Why Mivacurium is the Correct Answer:** Mivacurium belongs to the **benzylisoquinolinium** class of muscle relaxants. Unlike most other NMBAs, it is not metabolized by the liver. Instead, it is hydrolyzed by **plasma pseudocholinesterase** (butyrylcholinesterase). This results in a very short duration of action (approx. 15–20 minutes). Patients with a genetic deficiency of pseudocholinesterase or "atypical cholinesterase" will experience prolonged paralysis after receiving Mivacurium. **Analysis of Incorrect Options:** * **Pancuronium (Option A):** A long-acting steroid-based NMBA. It undergoes significant hepatic metabolism (deacetylation) and is primarily excreted by the kidneys. * **Vecuronium (Option B):** An intermediate-acting steroid-based NMBA. It is heavily dependent on hepatic metabolism and biliary excretion. * **Rocuronium (Option C):** An intermediate-acting steroid-based NMBA. It is primarily eliminated unchanged by the liver into the bile, with minimal renal excretion. **High-Yield Clinical Pearls for NEET-PG:** * **Hofmann Elimination:** Remember **Atracurium** and **Cisatracurium**. These are unique because they undergo spontaneous non-enzymatic degradation (Hofmann elimination) in the plasma, making them the drugs of choice in both **liver and kidney failure**. * **Shortest Acting NMBA:** Gantacurium (ultra-short), followed by Mivacurium (short). * **Steroid-based NMBAs:** (Pancuronium, Vecuronium, Rocuronium) all end in "-onium" and rely significantly on hepatic/renal clearance. * **Reversal:** Rocuronium and Vecuronium can be specifically reversed using **Sugammadex**.

Question 276: A patient suffers from troublesome allergic rhinitis due to pollen. Which drug, when prescribed, is least likely to cause sedation?

A. betamethasone
B. cimetidine
C. hydroxyzine
D. loratadine (Correct Answer)

Explanation: ### Explanation The question asks for the drug least likely to cause sedation among the options provided for treating allergic rhinitis. **Correct Answer: D. Loratadine** Loratadine is a **second-generation H1-antihistamine**. Unlike first-generation antihistamines, second-generation drugs are highly polar, have low lipid solubility, and are substrates for the P-glycoprotein efflux pump in the blood-brain barrier (BBB). Consequently, they do not cross the BBB in significant amounts, making them "non-sedating." This makes them the preferred choice for symptomatic relief in allergic rhinitis without impairing psychomotor performance. **Analysis of Incorrect Options:** * **A. Betamethasone:** This is a potent glucocorticoid. While it is used in allergic rhinitis (usually topically), it is not an antihistamine. While it doesn't cause sedation, it is not the primary "drug of choice" for immediate symptom relief compared to antihistamines in this context, and it carries a different side-effect profile (e.g., hypothalamic-pituitary-adrenal axis suppression). * **B. Cimetidine:** This is an **H2-receptor antagonist** used primarily to inhibit gastric acid secretion. It has no role in treating allergic rhinitis, as allergic symptoms are mediated by H1 receptors. * **C. Hydroxyzine:** This is a **first-generation H1-antihistamine**. These drugs are highly lipophilic and readily cross the BBB, causing significant sedation and anticholinergic side effects. **NEET-PG High-Yield Pearls:** * **Second-generation H1-blockers:** Loratadine, Cetirizine, Fexofenadine, Desloratadine, and Azelastine. * **Fexofenadine** is considered the least sedating of all because it has virtually zero CNS penetration. * **Cetirizine** is a metabolite of hydroxyzine; while it is second-generation, it may cause mild sedation in sensitive individuals compared to loratadine. * **Terfenadine and Astemizole** (older 2nd gen) were withdrawn due to **QT interval prolongation** (Torsades de pointes) when co-administered with CYP3A4 inhibitors like erythromycin or ketoconazole.

Question 277: Which of the following reactions to a drug is considered the least predictable?

A. Toxicity
B. Side effect
C. Idiosyncrasy (Correct Answer)
D. Allergy

Explanation: **Explanation:** The correct answer is **Idiosyncrasy**. **1. Why Idiosyncrasy is the correct answer:** Idiosyncrasy refers to a genetically determined abnormal reactivity to a chemical that is peculiar to an individual. Unlike side effects or toxicity, these reactions are **qualitatively abnormal** and do not occur in most patients even at high doses. Because they are rooted in rare genetic variations (e.g., enzyme deficiencies), they are the **least predictable** reactions and are not dose-dependent. **2. Why other options are incorrect:** * **Side Effects (B):** These are predictable, unavoidable pharmacological effects occurring at therapeutic doses. For example, dry mouth with atropine is expected. * **Toxicity (A):** This is a predictable exaggeration of the drug's therapeutic effect due to overdosage or prolonged use. It is strictly dose-dependent. * **Allergy (D):** While often unpredictable on the first exposure, drug allergies are immunologically mediated. Once a patient is sensitized, the reaction becomes "predictable" for that specific individual upon re-exposure. Idiosyncrasy remains less predictable overall as it often manifests without prior sensitization. **3. High-Yield Clinical Pearls for NEET-PG:** * **Classic Example of Idiosyncrasy:** Hemolysis caused by **Primaquine** or Sulfonamides in patients with **G6PD deficiency**. * **Succinylcholine Apnea:** Caused by an idiosyncratic genetic deficiency of **pseudocholinesterase**. * **Barbiturates:** Can trigger acute intermittent porphyria in susceptible individuals (Idiosyncratic reaction). * **Key Distinction:** Side effects and Toxicity are **Type A** (Augmented) reactions; Idiosyncrasy and Allergy are **Type B** (Bizarre) reactions. Among Type B, Idiosyncrasy is the most obscure.

Question 278: What is the typical number of patients enrolled in a Phase II clinical trial?

A. 10-100
B. 200-400 (Correct Answer)
C. 1000-2000
D. 2000-4000

Explanation: **Explanation:** In the drug development process, **Phase II Clinical Trials** (also known as the "Therapeutic Exploratory" phase) are primarily designed to evaluate the **efficacy** of a drug in a specific disease condition and to determine the optimal dosage range. 1. **Why Option B is correct:** Phase II trials typically involve a moderate number of participants, usually ranging from **100 to 500 patients** (with **200-400** being the most representative range for exam purposes). This sample size is large enough to provide a preliminary assessment of whether the drug works in patients who actually have the target disease, while still maintaining safety and cost-effectiveness before moving to large-scale Phase III trials. 2. **Why other options are incorrect:** * **Option A (10-100):** This range is characteristic of **Phase I trials**, which are conducted on a small group of healthy volunteers to assess safety, tolerability, and pharmacokinetics. * **Options C & D (1000-4000):** These large numbers are typical of **Phase III trials** (Therapeutic Confirmatory phase). These trials require thousands of patients across multiple centers to confirm efficacy and monitor for rarer adverse effects compared to a placebo or standard treatment. **High-Yield Clinical Pearls for NEET-PG:** * **Phase 0:** Microdosing (Human microdosing) to study pharmacokinetics; involves <15 subjects. * **Phase I:** Safety and Maximum Tolerated Dose (MTD). Usually done in healthy volunteers (Exception: Cytotoxic drugs). * **Phase II:** First time the drug is tested in **patients**. Focus is **Efficacy** and **Dose-finding**. * **Phase III:** Comparison with existing standard treatment; required for New Drug Application (NDA). * **Phase IV:** Post-marketing surveillance; detects rare/long-term adverse effects (e.g., Phocomelia with Thalidomide).

Question 279: Central Drugs Standard Control Organisation zonal offices are located in all of the following places except?

A. Mumbai
B. Chennai
C. Ahmedabad
D. Jaipur (Correct Answer)

Explanation: ### Explanation The **Central Drugs Standard Control Organisation (CDSCO)** is the National Regulatory Authority (NRA) of India, functioning under the Directorate General of Health Services, Ministry of Health & Family Welfare. **1. Why Jaipur is the Correct Answer:** As per the current organizational structure of CDSCO, there are **six Zonal Offices** located strategically across India to regulate the manufacture, sale, and distribution of drugs. **Jaipur** does not host a Zonal Office; instead, it houses a **Sub-Zonal Office**. Therefore, it is the "except" in this list. **2. Analysis of Incorrect Options (Existing Zonal Offices):** The six established Zonal Offices are: * **Mumbai (West Zone):** One of the oldest and primary regulatory hubs. * **Chennai (South Zone):** Manages regulatory affairs for the southern region. * **Ahmedabad (West Zone):** A critical zone given Gujarat's status as a pharmaceutical manufacturing hub. * **Ghaziabad (North Zone):** Covers the northern belt. * **Kolkata (East Zone):** Manages the eastern and north-eastern regions. * **Hyderabad (South Zone):** A major hub for vaccine and bulk drug regulation. **3. High-Yield Facts for NEET-PG:** * **Headquarters:** New Delhi. * **Head of CDSCO:** The **Drugs Controller General of India (DCGI)**. * **Key Functions:** Approval of new drugs, conduct of clinical trials, laying down standards for drugs, and coordinating the activities of State Drug Control Organizations. * **Sub-Zonal Offices:** Apart from Jaipur, other sub-zonal offices include Bangalore, Chandigarh, Indore, Patna, and Varanasi. * **Port Offices:** CDSCO also maintains offices at 13 air/sea ports (e.g., Nhava Sheva, Kandla) to monitor the import and export of drugs.

Question 280: What is the primary aim of a post-marketing study for a drug?

A. To determine the efficacy of the drug.
B. To establish the optimal dosage of the drug.
C. To investigate alterations in the drug's absorption, distribution, binding, or storage.
D. To identify rare adverse effects of the drug. (Correct Answer)

Explanation: **Explanation:** Post-marketing surveillance, also known as **Phase IV Clinical Trials**, occurs after a drug has been approved for public use. The primary objective is to monitor the drug's performance in the real world across a large, diverse population over a long duration. **Why Option D is correct:** Phase III trials typically involve only a few thousand patients, which is insufficient to detect **rare adverse drug reactions (ADRs)** (e.g., those occurring in 1 in 10,000 users) or long-term toxicities. Phase IV studies involve millions of patients, allowing for the identification of low-frequency side effects, drug-drug interactions, and safety in specific subgroups (elderly, pregnant women) that were excluded from earlier trials. **Why other options are incorrect:** * **Option A (Efficacy):** The therapeutic efficacy and "Proof of Concept" are primarily established in **Phase II** (small scale) and confirmed in **Phase III** (large scale) trials. * **Option B (Optimal Dosage):** Dose-ranging studies to find the maximum tolerated dose and optimal biological dose are the hallmark of **Phase I** and **Phase II** trials. * **Option C (Pharmacokinetics):** Investigating absorption, distribution, metabolism, and excretion (ADME) is the primary focus of **Phase I** trials (Human Pharmacology). **NEET-PG High-Yield Pearls:** * **Phase IV** has no fixed duration and no control group (observational). * It is the stage where **"Black Box Warnings"** are often added or drugs are **withdrawn** from the market (e.g., Rofecoxib due to cardiovascular risks). * **Phase 0:** Also called "Microdosing" studies; used to determine PK parameters using sub-therapeutic doses. * **Phase I:** Primarily tests **Safety** in healthy volunteers (except for oncology drugs).

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free